AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05026944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percussive massage and static stretching exercises
Description: All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be treated with 5 minutes of percussive massage and 5 minutes of static stretching exercises. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
Study NCT05026944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: static stretching exercises
Description: All the study participants will perform 15 minutes treadmill, 15 minutes stationary bicycle at day one. After 24 hours participants with positive DOMS will be managed with 5 minutes of static stretching exercises only. The group will be assessed on Numeric Pain Rating Scale and Short-Form McGill Pain Questionnaire for pain and degree of passive ankle dorsi flexion for calf muscle length at baseline before intervention and immediate 24 hours, 48 hours and 72 hours after the completion of treatment session.
Study NCT06423664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play and Learn Strategies (PALS) Program
Description: Monthly modules and personalized coaching sessions designed to strengthen maternal responsiveness and sensitivity which, in turn, improves infant social-emotional behavior and development outcomes.
Study NCT06423690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EAS1 System
Description: tumor ablation system in IRE method
Study NCT06663592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: hot pack, stretching of the neck muscles, cervical isometrics exercise
Study NCT06663592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tensioner Neuro Dynamic Mobilization
Description: Median nerve tensioner neural mobilization with addition to conventional treatment
Study NCT06663592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slider Neuro Dynamic Mobilization
Description: Median nerve neural sliding mobilization with addition to conventional treatment
Study NCT06336356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Baxdrostat will be administered orally once daily.
Study NCT06336356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally once daily.
Study NCT05653232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylaxis (P2W)
Description: For participants enrolled in P2W arm, the initial dose of SOF/VEL will be administered to the recipient when called to the operating room for transplant (typically 1-3 hours prior to the start of surgery). Post-transplant, SOF/VEL will be continued daily for 13 days post-KT (a total of 14 doses administered).
Study NCT05653232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transmit and Treat (T&T)
Description: For participants enrolled in T\&T arm, SOF/VEL will begin between post-KT day 0 and post-KT day 14. Participants will be clinically-prescribed DAAs once viremia is detected, and participant's insurance will be petitioned to obtain treatment as soon as possible. If insurance-provided DAAs are approved before post-KT day 14, participant will begin 12 weeks of study-provided SOF/VEL on date of insurance-provided DAAs approval. If insurance-provided DAAs are not approved by post-KT day 14, study-provided SOF/VEL will begin on post-KT day 14 and continue for 12 weeks.
Study NCT04535427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Study NCT04535427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Study NCT06037317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-3505
Description: LTK tyrosine kinase inhibitor
Study NCT06233786 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).
Study NCT06233786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).
Study NCT06589310 — intervention group
Intervention type: DEVICE
Intervention: Exact Sciences Multicancer Early Detection (MCED) Test
Description: Exact Sciences MCED test, is a qualitative in vitro diagnostic (IVD) for the detection of alterations in circulating tumor DNA and tumor-associated protein levels, which are commonly associated with cancer. It is performed on plasma derived from peripheral blood specimens.
Study NCT04777981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CBDRA60 supplement
Description: CBD is a non-psychotropic cannabinoid that has a broad spectrum of well-established anti-inflammatory and immunomodulatory effects. Red algae (Rhodophyta) are known for their potent anti-viral properties, non-toxicity and for being well tolerated in humans \[15, 16\]. Rhodophyta contain several sulfated polysaccharides that exhibit high antiviral activity against enveloped viruses.,
Study NCT04777981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05150431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: Parecoxib 40mg will be administered to the experimental group if the patient has no contraindication.
Study NCT05150431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is normal saline 2ml, which is equal to the volume of parecoxib solution. Placebo will be injected to placebo group 15 minutes before the end of the surgery.
Study NCT06679621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Description: This telehealth intervention will be made using human centered design methods
Study NCT06681428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allograft
Description: Placental-based Allografts
Study NCT06688799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Study NCT06716658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAK1 Inhibitor
Description: Golidocitnib 150mg QD orally, with a 28-day cycle. Efficacy will be evaluated once per cycle during the first year, and once every two cycles thereafter. Treatment will continue for up to 24 cycles, or until disease progression, lack of response within the first 6 cycles, or the occurrence of intolerable toxicity, whichever occurs first
Study NCT06715150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromcyin
Description: Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
Study NCT06715150 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
Study NCT06718335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Patients who meet the screening criteria will receive pyrotinib (400mg, qd) + trastuzumab injection (first dose 8mg/kg, subsequent 6mg/kg, d1) + albumin purpurenin.In adjuvant therapy, pathological complete response patients receive pyrotinib time to one year, non-pathological complete response patients with RCB-1 receive Trastuzumab Emtansine time to one year，RCB≥2 were treated with Trastuzumab Emtansine combined with pertuzumab time to one year.
Study NCT06728865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The treatment regimen is Furmonertinib combined with Bevacizumab.
Description: The treatment regimen is Furmonertinib combined with Bevacizumab.
Study NCT06728020 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Conventional rehabilitation (Group A)
Description: The conventional group will undergo standard rehabilitation treatment according to the rehabilitation plan developed by the rehabilitation team. This group will undergo 3 hours of rehabilitation per day and will carry out face-to-face rehabilitation following an impairment-based approach aimed at the treatment of motor-cognitive functions.
Study NCT06728020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROOMMATE 1st
Description: In addition to Group A, this group will have the bedside multimedia monitor apparatus to access informative, rehabilitation, and entertainment content. Additionally, this group will have a digital and innovation coach to receive support in using the technology.
Study NCT06728020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROOMMATE 2nd
Description: Once the first RCT of the cmRCT is completed, a pilot RCT will be initiated, randomizing 60 cases between Group A and this group. In addition to conventional treatment, this group will have a version of the ROOMMATE system integrated with inertial sensors worn on the hands and fingers to guide the serious games on the platform.
Study NCT06727630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRJ1-3024
Description: PRJ1-3024 is provided as capsules and is administered orally once a day
Study NCT06729229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Experimental - 2 portions of fish (280g) per week and placebo supplement (corn oil)
Study NCT06729229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement/Vitamins
Description: Experimental - Control lunch (no fish) and omega 3 supplement
Study NCT05759637 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 1mg DST
Description: measurement of cortisol levels after 1 mg of dexamethasone (DST) at 11 pm
Study NCT05225948 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mmHg. RIC will be conducted twice daily during the period of hospitalization.
Study NCT05225948 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mmHg. RIC will be conducted twice daily during the period of hospitalization.
Study NCT05343325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
Study NCT05343325 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: Low-dose radiotherapy: 1GY/1F, D1, D2, D8, D15, Q3W for two cycles. The total radiation dose will be GTV 8Gy/8F, GTVnd 8 Gy/8F.
Study NCT04925557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mayzent
Description: PET imaging to evaluate the effects of Mayzent on the microglia of the brain.
Study NCT04925557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrevus
Description: PET imaging to evaluate the effects of Ocrevus on the microglia of the brain.
Study NCT05934474 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peripheral venipuncture blood sampling, as part of standard care procedures
Description: Collection of 36 mL of blood
Study NCT05934474 — intervention group
Intervention type: OTHER
Intervention: Interview with a psychiatrist
Description: Research project data collection
Study NCT06422728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Anxiety Disorders
Description: The UP is planned in group therapy format and includes interventions on common transdiagnostic features. The sessions in the protocol are planned as follows:~Session 1 - Assessment: introduction, talking on group rules and the process, setting goals~Session 2 - Psychoeducation: the CBT model is introduced.~Session 3 - Emotions: the role of emotions are discussed.~Session 4, 5 \& 6 - Thoughts: the role of thoughts is mentioned. The participants learn to challenge unfunctional thoughts and generate alternative explanations. Also, exercises on excessive worry are applied.~Session 7 - Behaviors: the role of behaviors and the things that can/cannot be controlled are discussed.~Session 8 - Evaluation \& Maintaining Accomplishments: includes a review of what has been learnt during the group therapy and an evaluation on maintaining the accomplishments.~Session 9 - Follow-up session: one month later.
Study NCT06422728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Client-centered Supportive Therapy
Description: Client-entered therapy provides a non-directive supportive environment for the participants, that includes reflective listening and nonjudgmental and empathic communication. In this group, no CBT intervention will be applied. Through the supportive and non-directive environment, only the effect of relationship will be investigated as a common factor in psychotherapy.
Study NCT05604365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FearLess Intervention
Description: 8-12 weekly telehealth sessions one hour in length.The intervention includes psychotherapy techniques varying from relaxation response to self-regulation targeted to the specific fears of patients with glioma.
Study NCT06729229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator - Control lunch (no fish) and placebo supplement
Study NCT06729229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement/Vitamins
Description: Experimental - 2 portions of fish (280g) per week and omega 3 supplement
Study NCT06727786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious game training
Description: A serious game featuring a dramatic/realistic film, pauses with questions for active learning, and practice administration of naloxone and performing CPR
Study NCT06728566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inmersive virtual reality
Description: In addition to conventional training, IVR training aims to provide a detailed preview of the tasks and procedures required in the standard training with selected virtual scenarios:~Scenario 1: Inspection and Use of Personal Protective Equipment (PPE):~In this scenario, the worker will inspect the equipment to ensure it is in good condition and properly used: Harness, Helmet, Lanyards, Carabiners, Lifelines, Energy Absorbers~Scenario 2: Working on an Elevated Metal Structure:~Structure Ascent: Ascent Method: Use specific ascent systems, ensuring you are always connected to an anchor point.~Positioning on the Structure: Secure Anchorage: Once the working position is reached, secure the anchor to a fixed and reliable point.~Structure Descent: Unanchoring and Reanchoring: Unanchor and re-anchor at secure points as you descend.~Additional Safety Measures: Weather Conditions, signage and delimitation:~Scenario 3: Rescue at Heights: Accessing the Person in Danger, rescue Techniques.
Study NCT06728566 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: The working at heights training provided by the National Learning Service (SENA) in Colombia includes key steps to ensure safety and proper equipment use:~* Harness Use: Inspect for damage, wear it like a vest, and ensure correct orientation. Adjust shoulder and leg straps for comfort and secure the chest strap.~* Final Check: Verify D-rings are correctly positioned, and all buckles are securely fastened.~* Helmet: Inspect for damage and adjust for a secure fit.~* Lanyards: Select in good condition, connect properly, keep tension, and avoid overloading.~* Carabiners: Use certified carabiners with functioning locks, connected to proper points.~* Lifelines and Energy Absorbers: Install and tension lifelines properly; check energy absorbers before use.~* Climbing/Descending: Maintain three contact points and secure tools to avoid accidents.
Study NCT06728566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional training
Description: The working at heights training provided by the National Learning Service (SENA) in Colombia includes key steps to ensure safety and proper equipment use:~* Harness Use: Inspect for damage, wear it like a vest, and ensure correct orientation. Adjust shoulder and leg straps for comfort and secure the chest strap.~* Final Check: Verify D-rings are correctly positioned, and all buckles are securely fastened.~* Helmet: Inspect for damage and adjust for a secure fit.~* Lanyards: Select in good condition, connect properly, keep tension, and avoid overloading.~* Carabiners: Use certified carabiners with functioning locks, connected to proper points.~* Lifelines and Energy Absorbers: Install and tension lifelines properly; check energy absorbers before use.~* Climbing/Descending: Maintain three contact points and secure tools to avoid accidents.
Study NCT06199180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary vein isolation with RFA
Description: Patients randomised to RFA will undergo PVI with point-by-point RFA.
Study NCT06199180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulmonary vein isolation with PFA
Description: Patients randomised to PFA will undergo PVI with PFA.
Study NCT06316310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupoint thread embedding
Description: Acupoint embedding therapy:Main acupoints: Shangguan (CV-13), Xiaguan (CV-10), Tianshu (ST-25), Daheng (SP-15), Fenglong (ST-40), Qihai (CV-6), Zhongguan (CV-12), Zusanli (ST-36), Quchi (LI-11), Guanyuan (CV-4), Wailing (ST-26), Daju (ST-27), Shuidao (ST-28), Daimai (GB-26), Liangmen (ST-21), Ashi acupoints , where local fat accumulation in the abdomen. Methods of operation: With the patient in the prone position and all acupoints routinely sterilized, the acupuncturist will use sterile forceps to insert a 3-0 × 2-cm poly-p-dimethyl-hydroxy-oxazolone (PDO) thread into the tip of the #6 (0.6 mm × 60 mm) disposable embedded thread needle. The tissue around the area of the acupuncture point will be lifted with the thumb and forefinger of the non-dominant hand and the needle will be inserted into the acupuncture point to a depth of 1.5 cm with the dominant hand. Each treatment will last maximum of 10 minutes and the intervention will be repeated every 2 weeks for a total of 6 sessions.
Study NCT06316310 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: acupoint thread embedding
Description: Acupoint embedding therapy:Main acupoints: Shangguan (CV-13), Xiaguan (CV-10), Tianshu (ST-25), Daheng (SP-15), Fenglong (ST-40), Qihai (CV-6), Zhongguan (CV-12), Zusanli (ST-36), Quchi (LI-11), Guanyuan (CV-4), Wailing (ST-26), Daju (ST-27), Shuidao (ST-28), Daimai (GB-26), Liangmen (ST-21), Ashi acupoints , where local fat accumulation in the abdomen. Methods of operation: With the patient in the prone position and all acupoints routinely sterilized, the acupuncturist will use sterile forceps to insert a 3-0 × 2-cm poly-p-dimethyl-hydroxy-oxazolone (PDO) thread into the tip of the #6 (0.6 mm × 60 mm) disposable embedded thread needle. The tissue around the area of the acupuncture point will be lifted with the thumb and forefinger of the non-dominant hand and the needle will be inserted into the acupuncture point to a depth of 1.5 cm with the dominant hand. Each treatment will last maximum of 10 minutes and the intervention will be repeated every 2 weeks for a total of 6 sessions.
Study NCT06398158 — intervention group
Intervention type: DRUG
Intervention: Ravulizumab
Description: All study participants will receive commercially covered ravulizumab consistent with the indication, dose and frequency contained within the approved label.
Study NCT06331637 — intervention group
Intervention type: PROCEDURE
Intervention: Transanal Transection and Single-Stapled anastomosis (TTSS)
Description: Restorative proctectomy with Transanal Transection and Single-Stapled (TTSS) Ileal Pouch-Anal Anastomosis (IPAA)
Study NCT06331637 — intervention group
Intervention type: PROCEDURE
Intervention: Double-stapled anastomosis
Description: Restorative proctectomy with Tdouble-stapled Ileal Pouch-Anal Anastomosis (IPAA)
Study NCT05180539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPLASH Intervention Condition
Description: Two-session in person group discussions focusing on behaviors in drinking contexts